|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
62,030,000 |
Market
Cap: |
271.69(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$4.48 - $21.47 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is MGC018, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing enoblituzumab, an Fc-optimized monoclonal antibody that targets B7-H3 and molecules that target programmed cell death protein 1, a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
350,000 |
2,394,399 |
Total Buy Value |
$0 |
$0 |
$1,722,425 |
$11,462,434 |
Total People Bought |
0 |
0 |
1 |
2 |
Total Buy Transactions |
0 |
0 |
2 |
11 |
Total Shares Sold |
168,303 |
293,400 |
293,400 |
298,772 |
Total Sell Value |
$3,127,242 |
$4,995,238 |
$4,995,238 |
$5,027,631 |
Total People Sold |
4 |
5 |
5 |
5 |
Total Sell Transactions |
6 |
11 |
11 |
12 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Stein Kathryn E |
SVP, Product Dev. & Regulatory |
|
2014-12-22 |
4 |
OE |
$0.07 |
$777 |
D/D |
10,946 |
54,151 |
|
- |
|
Risser Eric Blasius |
VP, Business Development |
|
2014-12-22 |
4 |
OE |
$38.25 |
$191,250 |
D/D |
5,000 |
0 |
|
- |
|
Risser Eric Blasius |
VP, Business Development |
|
2014-12-22 |
4 |
OE |
$0.94 |
$4,700 |
D/D |
5,000 |
5,000 |
|
- |
|
Koenig Scott |
President and CEO |
|
2014-12-19 |
4 |
OE |
$0.94 |
$58,473 |
I/I |
62,205 |
703,414 |
|
- |
|
Stein Kathryn E |
SVP, Product Dev. & Regulatory |
|
2014-12-18 |
4 |
AS |
$33.00 |
$361,218 |
D/D |
(10,946) |
43,205 |
|
- |
|
Stein Kathryn E |
SVP, Product Dev. & Regulatory |
|
2014-12-18 |
4 |
OE |
$0.71 |
$7,772 |
D/D |
10,946 |
54,151 |
|
- |
|
Risser Eric Blasius |
VP, Business Development |
|
2014-12-18 |
4 |
AS |
$33.50 |
$335,000 |
D/D |
(10,000) |
0 |
|
- |
|
Risser Eric Blasius |
VP, Business Development |
|
2014-12-18 |
4 |
OE |
$0.94 |
$9,400 |
D/D |
10,000 |
10,000 |
|
- |
|
Risser Eric Blasius |
VP, Business Development |
|
2014-11-24 |
4 |
AS |
$27.75 |
$277,500 |
D/D |
(10,000) |
0 |
|
- |
|
Risser Eric Blasius |
VP, Business Development |
|
2014-11-24 |
4 |
OE |
$0.94 |
$9,400 |
D/D |
10,000 |
10,000 |
|
- |
|
Stein Kathryn E |
Senior VP, Prd Dev & Reg Aff |
|
2014-11-21 |
4 |
AS |
$27.00 |
$295,542 |
D/D |
(10,946) |
43,205 |
|
- |
|
Stein Kathryn E |
Senior VP, Prd Dev & Reg Aff |
|
2014-11-21 |
4 |
OE |
$0.71 |
$7,772 |
D/D |
10,946 |
54,151 |
|
- |
|
Stein Kathryn E |
Senior VP, Prd Dev & Reg Aff |
|
2014-11-17 |
4 |
AS |
$22.95 |
$47,966 |
D/D |
(2,090) |
43,205 |
|
- |
|
Stein Kathryn E |
Senior VP, Prd Dev & Reg Aff |
|
2014-11-17 |
4 |
OE |
$0.94 |
$1,965 |
D/D |
2,090 |
45,295 |
|
- |
|
Bonvini Ezio |
Senior VP, Research |
|
2014-11-14 |
4 |
OE |
$0.71 |
$2,769 |
D/D |
3,900 |
36,390 |
|
- |
|
Stein Kathryn E |
Senior VP, Prd Dev & Reg Aff |
|
2014-11-14 |
4 |
AS |
$23.33 |
$541,513 |
D/D |
(23,211) |
43,205 |
|
- |
|
Stein Kathryn E |
Senior VP, Prd Dev & Reg Aff |
|
2014-11-14 |
4 |
OE |
$0.94 |
$21,818 |
D/D |
23,211 |
66,416 |
|
- |
|
Risser Eric Blasius |
VP, Business Development |
|
2014-11-13 |
4 |
AS |
$25.00 |
$250,000 |
D/D |
(10,000) |
0 |
|
- |
|
Risser Eric Blasius |
VP, Business Development |
|
2014-11-13 |
4 |
OE |
$0.94 |
$9,400 |
D/D |
10,000 |
10,000 |
|
- |
|
Risser Eric Blasius |
VP, Business Development |
|
2014-11-12 |
4 |
AS |
$23.00 |
$345,000 |
D/D |
(15,000) |
0 |
|
- |
|
Risser Eric Blasius |
VP, Business Development |
|
2014-11-12 |
4 |
OE |
$0.94 |
$9,400 |
D/D |
10,000 |
15,000 |
|
- |
|
Saran Atul |
See remarks |
|
2014-10-28 |
4 |
D |
$21.79 |
$18,848 |
D/D |
(865) |
21,635 |
|
- |
|
Bonvini Ezio |
Senior VP, Research |
|
2014-10-10 |
4 |
OE |
$0.71 |
$284 |
D/D |
400 |
32,890 |
|
- |
|
Bonvini Ezio |
Senior VP, Research |
|
2014-10-09 |
4 |
OE |
$0.71 |
$1,891 |
D/D |
2,663 |
32,490 |
|
- |
|
Bonvini Ezio |
Senior VP, Research |
|
2014-10-08 |
4 |
OE |
$0.94 |
$1,501 |
D/D |
1,597 |
29,827 |
|
- |
|
286 Records found
|
|
Page 11 of 12 |
|
|